



pRetroX-Tight-Pur-Luc Vector Map.

Description

pRetroX-Tight-Pur-Luc is a retroviral control vector that expresses firefly luciferase under the control of P_{Tight} , a modified Tet-responsive promoter. P_{Tight} consists of seven direct repeats of a 36 bp regulatory sequence that contains the 19 bp tet operator sequence (*tetO*), and a modified minimal CMV promoter (1). This vector is supplied with our Retro-X™ Tet-On® and Tet-Off® Advanced Inducible Expression Systems (Cat. Nos. 632104 and 632105). These systems provide ready access to the inducible gene expression strategy of Gossen & Bujard, and incorporate major improvements described by Urlinger, *et al.* (2-6).

pRetroX-Tight-Pur-Luc is optimized to eliminate promoter interference through LTR self-inactivation. The hybrid 5' LTR consists of the cytomegalovirus (CMV) type I enhancer and the mouse sarcoma virus (MSV) promoter. This promoter drives high levels of viral genome transcription in HEK 293-based packaging cell lines due, in part, to the presence of adenoviral E1A (7-8) in these cells. The self-inactivating feature of the vector is provided by a deletion in the 3' LTR enhancer region (U3). During reverse transcription of the retroviral RNA, a copy of the inactivated 3' LTR U3 region replaces the corresponding region of the 5' LTR, resulting in the inactivation of the 5' LTR CMV enhancer sequence. This mechanism can reduce the phenomenon known as promoter interference (9-10) and allow more efficient expression. In this way, pRetroX-Tight-Hyg-Luc supports high viral titers, yet eliminates potential downstream interference between the inducible P_{Tight} promoter and its adjacent viral LTR.

pRetroX-Tight-Pur-Luc contains all of the necessary viral RNA processing elements; these include the 5' and 3' LTRs, the packaging signal (Ψ^+), and the tRNA primer binding site. For safety reasons, however, the vector lacks the structural genes (*gag*, *pol*, and *env*) necessary for retroviral particle formation and replication. pRetroX-Tight-Pur-Luc contains a puromycin resistance gene (*Pur^r*) under the control of the murine phosphoglycerate kinase (PGK) promoter (P_{PGK}) for the selection of stable transfectants. In addition, the vector contains a ColE1 origin of replication and an *E. coli* *Amp^r* gene for propagation and selection in bacteria.

(PR063564; published 1 July 2010)



Clontech

United States/Canada
800.662.2566

Asia Pacific
+1.650.919.7300

Europe
+33.(0)1.3904.6880

Japan
+81.(0)77.543.6116

Clontech Laboratories, Inc.
A Takara Bio Company
1290 Terra Bella Ave.
Mountain View, CA 94043
Technical Support (US)
E-mail: tech@clontech.com
www.clontech.com

Use

pRetroX-Tight-Pur-Luc can be used as a control vector for either plasmid or retroviral expression vectors. When used as a control for retroviral expression vectors, it must be transfected into a packaging cell line, such as GP2-293; we recommend the Retro-X Universal Packaging System (Cat. No. 631530). Packaging cell lines allow you to produce infectious, replication-incompetent retroviral particles. These retroviral particles can infect a wide range of target cells, but they cannot replicate within these cells due to the absence of viral structural genes. The separate introduction and integration of the structural genes into the packaging cell line minimizes the chance of producing replication-competent virus due to recombination events during cell proliferation.

Location of Features

- 5' LTR (CMV/MSV): 1–728
 - U3 region, containing a Cytomegalovirus (CMV)/ mouse sarcoma virus (MSV) hybrid promoter: 1–584
 - R region: 585–655
 - U5 region: 656–728
- ψ^+ (extended packaging signal): 759–1568
- P_{Tight} (modified Tet-responsive promoter): 1603–1918
- TATA box: 1880–1886
- Luciferase gene: 1935–3587
- P_{PGK} (phosphoglycerate kinase promoter): 3603–4106
- Puromycin resistance gene (P_{Pur}): 4127–4726
- 3' MMLV LTR (with a deletion in U3): 4907–5332
 - Poly A signal: 5234–5239
- P_{SV40} : 5612–5879
- SV40 origin of replication: 5833–5898
- ColE1 origin of replication: 6220
- Ampicillin resistance gene (β -lactamase): 6979–7839 (complementary)

Sequencing primer location

- P_{Tight} Sequencing Primer: 1579–1602
 - Primer Sequence: 5'-ATCTGAGGCCCTTTCGTCTTCACT-3'

Selection of Stable Transfectants

- Selectable marker: plasmid confers resistance to puromycin.

Propagation in *E. coli*

- Suitable host strains: DH5 α^{TM} , DH10B $^{\text{TM}}$, and other general purpose strains.
- Selectable marker: plasmid confers resistance to ampicillin (100 $\mu\text{g/ml}$) in *E. coli* hosts.
- *E. coli* replication origin: ColE1
- Copy number: high

Notes:

The vector sequence was compiled from information in the sequence databases, published literature, and other sources, together with partial sequences obtained by Clontech. This vector has not been completely sequenced.

The viral supernatants produced by this retroviral vector could contain potentially hazardous recombinant virus. Due caution must be exercised in the production and handling of recombinant retrovirus. Appropriate NIH, regional, and institutional guidelines apply.

References

1. pTRE-Tight Vectors (April 2003) *Clontechniques XVIII*(3):13-14.
2. Gossen, M. & Bujard, H. (1992) *Proc. Natl. Acad. Sci. USA* **89**(12):5547-5551.
3. Gossen, M., *et al.* (1995) *Science* **268**(5218):1766-1769.
4. Urlinger, S. *et al.* (2000) *Proc. Natl. Acad. Sci. USA* **97**(14):7963-7968.
5. Inducible Gene Expression Systems (January 2007) *Clontechniques XXII*(1):1-2.
6. Tet-On Advanced Inducible Gene Expression System (2006) *Clontechniques XXI*(2):1-3.
7. Ory, D.S. *et al.* (1996) *Proc. Natl. Acad. Sci. USA* **93**(21):11400-11406.
8. Pear, W.S. *et al.* (1993) *Proc. Natl. Acad. Sci. USA* **90**(18):8392-8396.
9. Barton, G.M. & Medzhitov R. (2002) *Proc. Natl. Acad. Sci. USA* **99**(23):14943-14945.
10. Emerman, M. & Temin, H.M. (1984) *Cell* **39**(3 pt. 2):449-467.

Notice to Purchaser

Clontech products are to be used for research purposes only. They may not be used for any other purpose, including, but not limited to, use in drugs, *in vitro* diagnostic purposes, therapeutics, or in humans. Clontech products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products or to provide a service to third parties without written approval of Clontech Laboratories, Inc.

Use of the Tetracycline controllable expression systems (the "Tet Technology") is covered by a series of patents including U.S. Patent Nos. 5,464,758 and 5,814,618, which are proprietary to TET Systems GmbH & Co. KG. Academic research institutions are granted an automatic license with the purchase of this product to use the Tet Technology only for internal, academic research purposes, which license specifically excludes the right to sell, or otherwise transfer, the Tet Technology or its component parts to third parties. Notwithstanding the above, academic and not-for profit research institutions whose research using the Tet Technology is sponsored by for profit organizations, which shall receive ownership to all data and results stemming from the sponsored research, shall need a commercial license agreement from TET Systems in order to use the Tet Technology. In accepting this license, all users acknowledge that the Tet Technology is experimental in nature. TET Systems GmbH & Co. KG makes no warranties, express or implied or of any kind, and hereby disclaims any warranties, representations, or guarantees of any kind as to the Tet Technology, patents, or products. All others are invited to request a license from TET Systems GmbH & Co. KG prior to purchasing these reagents or using them for any purpose. Clontech is required by its licensing agreement to submit a report of all purchasers of the Tet-controllable expression system to TET Systems. For license information, please contact: GSF/CEO, TET Systems GmbH & Co. KG, Im Neuenheimer Feld 582, 69120 Heidelberg, Germany Tel: +4962215880400, Fax: +4962215880404 eMail: info@tetsystems.com or use the electronic licensing request form via http://www.tetsystems.com/main_inquiry.htm

DH5 α [™] and DH10B[™] are trademarks of Life Technologies Corporation.

Clontech, Clontech logo and all other trademarks are the property of Clontech Laboratories, Inc. unless noted otherwise. Clontech is a Takara Bio Company. ©2010 Clontech Laboratories, Inc.